EGAGenomicsRNASeqhttps://ega-archive.org/studies/EGAS00001005980EGAEGA study EGAS00001005980Unravelling the contribution of HIF pathway and its therapeutic potential in human AML leukemia-initiating cellsEGArestrictedTherapy, leukemia, human being, Potential, acute non lymphoblastic leukemia, Myeloid, Modern, Hypoxia Inducible Factor Family, HIF Family, Leukemias, Human, AML, acute non lymphoblastic leukaemia, Homo sapiens, leukaemia NOS, Cell., acute myeloid, Leucocythaemia, aml1-evi-1, cbfa2, leukaemia, evi-1, Man, Hypoxia Inducible Factor, Leucocythaemias, Runx-1, aml, Acute myelogenous leukemia, Contributing, Leucocythemia, Leukemia, Man (Taxonomy), Myeloblastic, Xaml1, Acute Myeloblastic Leukemia, susceptibility to, Contributory, Hypoxia-Inducible Factor, Acute Myeloid Leukemia, Leucocythemias, amlcr1, Treatments, pebp2ab, aml1, human, XAML, HIF, Acute, Therapeutic, Modern Man, aml-1, Therapies, Treatment, ANLL, HIF Factor, Contribute, Hypoxia-Inducible Factor Family, Contribution, acute myelogenousd230, Disorders, human being, Date of Diagnosis, acute non lymphoblastic leukemia, Myeloid, Potential, chemotherapy, Deficiencies, dTAFII250, pharmacotherapy, Pharmacotherapies, EfW1, Diagnosis, Chemotherapies, disease type, Human, Oxygen Deficiency, Oxygen Deficiencies, dmTAF[[II]]230, Relative, Client., acute non lymphoblastic leukaemia, Homo sapiens, dmTAF1, Taf230, symptoms, acute myeloid, Hypoxia, Drug Therapies, Man, gene expression, TAF250, Runx-1, study, Targeting, Taf200, Leukemia, dTAF[[II]]250, Supply, Man (Taxonomy), TFIID TAF250, Diagnostic, cel, DIAG, cell, Acute Myeloblastic Leukemia, C1, Provide, Target, Matched, Taf1p, amlcr1, pebp2ab, aml1, XAML, Oxygen, dTAF250, Supplied, Other Disease, Clients, Disorder, Therapies, disorder, ANLL, Expression, TAF, Comprehensive, acute myelogenous, TARGET, date of diagnosis, leukemia, Therapy, screening, SINGLE, Disease, dTAF[[II]]230, TAF[[II]]250, target_lesion, findings, Target Lesion Identification, Index, Diagnosed, Modern, Matching, date_of_diagnosis, Targeted, TAF200, l(3)84Ab, function, BG:DS00004.13, TAFII-250, TAF250/230, Client, Cell, AML, dTAF230, DIAGNOSIS, Gene Expression, Anoxia, TAFII250, disease_type, diagnosis, p230, Relative Risks, Disease or Disorder, Diseases, TAF[[II]]250/230, Chemotherapy, TFIID, condition, Dx, aml1-evi-1, cbfa2, evi-1, Relative Risk, aml, Destination, Taf[[II]]250, Acute myelogenous leukemia, Single Person, TAF[[II]]230, Pharmacotherapy, Non-Neoplastic, Risk, Myeloblastic, Xaml1, susceptibility to, Match, disease term, Risks, Hypoxemia, Acute Myeloid Leukemia, signs, TAF[II]250, patient, CG17603, TAF[[II]], Treatments, human, Atlases, Drug, disease, Deficiency, Acute, DmelCG17603, Therapeutic, Only, Taf250, Expressed, Patient, SR3-5, Diseases and Disorders, Modern Man, aml-1, target lesion, Treatment, Solitary, pharmacologic therapy, Single, disease_term, Anoxemia, Provided, Alone, TAF230, TAF1falseUnravelling the contribution of HIF pathway and its therapeutic potential in human AML leukemia-initiating cellsThis study hypothesized that hypoxia contributes to AML-LSCs function and represents a potential therapeutic target to sensitize AML-LSCs to chemotherapy. We provide a comprehensive single-cell expression atlas of AML patient-matched diagnostic-relapsed samples from risk-stratified human AML patients.2022-02-01 16:15:58EGAS000010059809606EGAD00001008514EGAC00001002509